Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
NCT00812019
Completed
The aim of the present dose ranging study is to evaluate the safety, tolerability and immunogenicity of two doses of twelve different formulations of a Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine, adjuvanted with MF59 or non-adjuvanted, given three weeks apart and followed by a booster dose after 12 months in healthy adults 18 to 40 years of age.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/20/2020
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Influenza
Register for Updates
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
NCT00004880
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2020
Locations: Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
Conditions: Kidney Cancer
Register for Updates
Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
NCT01122784
Completed
Multicenter, randomized, single-blinded comparison of two formulations of the rF1V vaccine at a single dosage of 80 µg and two 3-dose schedules in 400 healthy, adult volunteers in four parallel cohorts. Two rF1V vaccine cohorts (N=160 each) and two rF1V antigen-only cohorts (N=40 each) will be vaccinated at two different three-dose schedules (Days 0, 56 and 182 or Days 0, 56 and 121).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/28/2020
Locations: Benchmark Research, San Francisco, California +10 locations
Conditions: Plague Vaccine
Register for Updates
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
NCT02775292
Completed
This phase I trial studies the side effects and the best dose of nivolumab when given together with gene-modified T cells and vaccine therapy in treating patients with solid tumors that express the cancer-testes antigen NY-ESO-1 gene AND have spread from where it started to nearby tissue or lymph nodes (locally advanced) or distant organs (stage IV). T cells are a special type of white blood cells (immune cell) that have the ability to kill cancer cells. Nivolumab may block PD-1 which is found o... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/22/2020
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Register for Updates
Vaccination Efficacy With Metformin in Older Adults
NCT03996538
Completed
With aging the immune system gets weaker. This makes older adults more susceptible to influenza (flu). Vaccinations help to prevent infection from the flu virus, however the immune system of older adults do not respond as well to vaccines compared to young adults and thus, aren't as well protected from the complications from the flu. This research is being done to determine if Metformin, an FDA-approved diabetes medication, is effective at enhancing immune responses to flu vaccine in older men a... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/22/2020
Locations: UConn Health, Farmington, Connecticut
Conditions: Aging, Age-Related Immunodeficiency, Vaccine Response Impaired
Register for Updates
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
NCT03314662
Completed
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/20/2020
Locations: Coastal Clinical Research, Inc., Mobile, Alabama +19 locations
Conditions: Influenza, Human
Register for Updates
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
NCT03318315
Completed
This is a randomized, un-blinded, Phase II study in males and non-pregnant females, who are in good health, 19 to 64 years of age. This study is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic AS03 (GSK) adjuvanted 2017 monovalent inactivated influenza A/H7N9 vaccine, when two doses are administered 21 days apart either sequentially or simultaneously (within 15 minutes) with licensed seasonal influenza vaccine. Subjects will be randomized into one of three tre... Read More
Gender:
ALL
Ages:
Between 19 years and 64 years
Trial Updated:
07/16/2020
Locations: University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham, Alabama +3 locations
Conditions: Avian Influenza, Influenza, Influenza Immunisation
Register for Updates
BARDA Securing Anthrax Immunity For the Elderly
NCT03518125
Completed
This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2020
Locations: Johnson County Clin-Trials, Lenexa, Kansas +3 locations
Conditions: Anthrax
Register for Updates
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
NCT02114333
Completed
This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the body's immune response to the vaccine, and is currently investigational. The vaccines are being compared to assess their ability to stimulated protection against shingles. The study will provide an opp... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
07/07/2020
Locations: Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine, Aurora, Colorado
Conditions: Shingles, Herpes Zoster
Register for Updates
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
NCT03497845
Completed
The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains. The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvan... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
06/30/2020
Locations: Optimal Research, San Diego, California +5 locations
Conditions: Influenza A Virus, H5N1 Subtype
Register for Updates
Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults
NCT03039491
Completed
The investigators hypothesized that pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13 (Prevnar-13) followed by PPV-23 results in a similar antibody levels/functional antibody activity and induce similar pneumococcal polysaccharide (PPS)-specific B cell response in HIV positive individuals \> 50 years of age, HIV positive individuals 21-40 years of age as compared to HIV negativ... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/12/2020
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: HIV Lipodystrophy, Aging
Register for Updates
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
NCT01272180
Completed
This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
06/11/2020
Locations: Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615, Birmingham, Alabama +12 locations
Conditions: Invasive Meningococcal Disease
Register for Updates